Is Germany closing in on the U.S. funding gap?

Biotech VC financings in Germany and USA have shown the same positive development over the past five years.  In 2020, both countries have increased their biotech VC financings compared to the previous year 2019.

But appearances are deceptive: In 2020, CureVac has raised a massive crossover round of EUR 560m. Without CureVac’s transaction, biotech VC financings in Germany would have decreased by -20%.

Germany could well need more transactions such as CureVac to close the gap with the USA and reduce the funding deficit of 24x.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: